NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results, Beats Expectations By $2.11 EPS

NuCana (NASDAQ:NCNA) issued its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11, Zacks reports.

NuCana Trading Down 4.5 %

Shares of NASDAQ NCNA traded down $0.04 during midday trading on Thursday, reaching $0.81. 30,468 shares of the company were exchanged, compared to its average volume of 419,991. The stock has a market cap of $2.13 million, a P/E ratio of -0.08 and a beta of 0.89. NuCana has a 1 year low of $0.75 and a 1 year high of $10.79. The stock has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.57.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.